Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Haleon PLC ( (GB:HLN) ) has issued an update.
Haleon PLC has announced the purchase of 1,504,400 ordinary shares for cancellation as part of the second tranche of its share buyback program. This move is expected to impact the company’s share capital and voting rights, with implications for shareholders under the FCA’s Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £350.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.
Haleon PLC’s overall stock score reflects strong financial performance and strategic corporate actions like share buybacks and dividend increases. However, technical indicators suggest potential bearish momentum, and challenges in the North American market pose risks. The company’s valuation is fair, with moderate P/E and dividend yield.
To see Spark’s full report on GB:HLN stock, click here.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with a product portfolio that includes Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. The company is known for its trusted brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.
Average Trading Volume: 22,013,189
Technical Sentiment Signal: Hold
Current Market Cap: £31.97B
See more insights into HLN stock on TipRanks’ Stock Analysis page.